Propanc Health Group Corporation — Form 10-Q
Reporting period: Quarter and nine months ended March 31, 2012; filed May 21, 2012. The filing identifies the company as a development-stage cancer-treatment developer operating through its Australian subsidiary. It reports no marketed products and no products in clinical trials.
Financial results and liquidity
| Metric | Three months ended Mar. 31, 2012 | Nine months ended Mar. 31, 2012 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $3,094,699 | $9,045,343 |
| Net loss | $3,096,178 | $8,875,611 |
| Net loss per share, basic and diluted | $0.04 | $0.12 |
| Net cash used in operations | Not presented for the quarter | $114,321 |
- At March 31, 2012, cash was $39,474; total assets were $2,158,692, including $2,086,034 of prepaid expenses and other current assets, principally prepaid stock-based consulting services.
- Current liabilities totaled $482,227, including $143,161 of convertible debentures and amounts due to directors and other related parties. No long-term liabilities were reported.
- Stockholders’ equity was $1,676,465, versus $10,507,309 at June 30, 2011. Accumulated development-stage deficit was $12,721,951.
- The nine-month operating cash use was far below the reported net loss, mainly because $8,485,217 of prepaid stock issued for services was amortized as an expense without a corresponding current-period cash outflow. Financing provided $153,708; investing used no cash.
Changes versus prior comparable periods
- For the nine months, net loss increased to $8,875,611 from $1,498,293, while operating expenses rose to $9,045,343 from $1,579,736. Management attributed the increase primarily to amortization of prepaid stock issued for services.
- Research and development expense fell to $5,317 from $362,585 for the nine-month periods. Management said the decrease reflected the timing of resumed development activity after securities registration.
- For the March quarter, net loss increased to $3,096,178 from $508,439; the company attributed the increase mainly to prepaid stock-service amortization.
- Cash increased from $132 at June 30, 2011 to $39,474 at March 31, 2012, while total assets fell from $10,814,158, largely as the prepaid consulting balance was amortized.
Outlook, risks and unusual items
- Funding and going concern: Management estimated approximately $7.5 million would be needed to fund operations and the development program over the next 12–18 months. It said cash on hand was expected to fund operations only until June 2012 and that the company did not have enough cash to continue for the next 12 months. The filing states that these conditions raise substantial doubt about the company’s ability to continue as a going concern; additional financing is not assured.
- Development and regulatory risk: The lead product was in preclinical activities. Development success, patent protection, financing, and future sales remain uncertain. The company reported no clinical-stage products and no product revenue.
- Convertible debt: Debentures issued in August and December 2011 and March 2012 provided $147,000 of stated cash proceeds. They carried 5% interest, were due six months after issuance, and were convertible at $1.50 per share. The March 31 balance, after currency translation, was $143,161.
- Subsequent equity activity: In April 2012 the company sold 21,800 shares for approximately $14,000 and issued shares to consultants, including 200,000 shares valued at $130,000, 150,000 valued at $97,500, and 200,000 valued at $130,000 for future services. It also issued 150,000 warrants exercisable at $1.00 per share. These transactions followed the quarter end.
- Controls: Management concluded disclosure controls were not effective because of a material weakness: limited staffing prevented sufficient segregation of duties. The company planned to address this by hiring accounting personnel when resources permitted.
- Other matters: The filing reported no pending or threatened material lawsuits, no defaults on senior securities, and no off-balance-sheet arrangements. It identified uninsured Australian bank deposits and foreign-currency translation exposure.
Key facts investors should verify
- Availability, timing, and terms of additional financing, including whether the stated $7.5 million funding need was met.
- Cash runway and subsequent liquidity; the filing’s cash-runway statements distinguish funding only until June 2012 from the 12-month funding shortfall.
- Progress and costs of preclinical research, and the status of the international patent application and related protection.
- The accounting support, service periods, and remaining balance for the large prepaid stock-service asset and related amortization.
- Post-quarter share and warrant issuances, their expense recognition, and resulting dilution; the filing reports 72,153,276 shares outstanding at March 31, 2012 and 72,780,880 as of May 18, 2012.
- Whether the control weakness was remediated and whether going-concern uncertainty continued in later filings.